A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.

Mark Milton – Edwards Global Dir. Respiratory, TEVA

FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

Last October, Wouter van Geffen, pulmonologist at the Medical Center Leeuwarden, The Netherlands, was awarded his PhD degree for this
Read More
Jan de Backer, MSc,PhD,MBA. CEO of FLUIDDA recently became member of the advisory board of the RIS. The Respiratory Innovation
Read More
From May 7-10 the Respiratory Drug Delivery congress (RDD) will take place in Estoril, Portugal. This annual congress is focussed
Read More
On Friday May 17, just before the start of the annual congress of the American Thoracic Society (ATS) in Dallas,
Read More